R
Richard Wooster
Researcher at GlaxoSmithKline
Publications - 87
Citations - 12344
Richard Wooster is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 36, co-authored 87 publications receiving 11801 citations. Previous affiliations of Richard Wooster include Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Identification of the breast cancer susceptibility gene BRCA2
Richard Wooster,Graham R. Bignell,Johnathan M. Lancaster,Sally Swift,Sheila Seal,Jonathon Mangion,N. Collins,Simon G. Gregory,Curtis Gumbs,Gos Micklem +9 more
TL;DR: The identification of a gene in which six different germline mutations in breast cancer families that are likely to be due to BRCA2 are detected, and results indicate that this is the BRC a2 gene.
Journal ArticleDOI
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
Richard Wooster,Susan L. Neuhausen,Jonathan Mangion,Yvette Quirk,D Ford,N. Collins,K. Nguyen,Sheila Seal,T.D. Tran,D. Averill,P Fields,Gill Marshall,Steven A. Narod,Gilbert M. Lenoir,Henry T. Lynch,Jean Feunteun,Peter Devilee,Cees J. Cornelisse,Fred H. Menko,Peter A. Daly,Wilma Ormiston,Ross McManus,Carole Pye,Cathryn M. Lewis,Lisa A. Cannon-Albright,Julian Peto,Bruce A.J. Ponder,Mark H. Skolnick,Douglas F. Easton,David E. Goldgar,Michael R. Stratton +30 more
TL;DR: This analysis localized a second breast cancer susceptibility locus, BRCA2, to a 6-centimorgan interval on chromosome 13q12-13, which preliminary evidence suggests suggests confers a high risk of breast cancer but does not confer a substantially elevated risk of ovarian cancer.
Journal ArticleDOI
Erratum: Identification of the breast cancer susceptibility gene BRCA2
Richard Wooster,Graham R. Bignell,Jonathan Lancaster,Sally Swift,Sheila Seal,Jonathan Mangion,N. Collins,Simon G. Gregory,Curtis Gumbs,Gos Michlem,Rita Barfoot,Rifat Hamoudi,Sandeep Patel,Catherine M. Rice,Patrick J. Biggs,Yasmin Hashim,Amanda Smith,Frances Connor,Adelgeir Arason,Julius Gudmundsson,David Ficenec,David P. Kelsell,D Ford,Patricia N. Tonin,D. Timothy Bishop,Nigel K. Spurr,Bruce A.J. Ponder,Rosalind A. Eeles,Julian Peto,Peter Devilee,Cees J. Cornelisse,Henry T. Lynch,Steven A. Narod,Gilbert M. Lenoir,Valdgardur Egilsson,Rosa Bjork Barkadottir,Douglas F. Easton,David R. Bentley,P. Andrew Futreal,Alan Ashworth,Michael R. Stratton +40 more
Journal ArticleDOI
Subtype and pathway specific responses to anticancer compounds in breast cancer.
Laura M. Heiser,Anguraj Sadanandam,Wen-Lin Kuo,Stephen C. Benz,Theodore C. Goldstein,Sam Ng,William J. Gibb,Nicholas J. Wang,Safiyyah Ziyad,Frances Tong,Nora Bayani,Zhi Hu,Jessica Billig,Andrea Dueregger,Sophia Lewis,Lakshmi Jakkula,James E. Korkola,Steffen Durinck,François Pepin,Yinghui Guan,Elizabeth Purdom,Pierre Neuvial,Henrik Bengtsson,Kenneth Wood,Pete Smith,Lyubomir T. Vassilev,Bryan T. Hennessy,Joel Greshock,Kurtis E. Bachman,Mary Ann Hardwicke,John W. Park,Laurence J. Marton,Denise M. Wolf,Eric A. Collisson,Richard M. Neve,Gordon B. Mills,Terence P. Speed,Heidi S. Feiler,Richard Wooster,David Haussler,Joshua M. Stuart,Joe W. Gray,Paul T. Spellman +42 more
TL;DR: In this paper, a test of 77 therapeutic compounds, nearly all drugs showed differential responses across these cell lines, and approximately one third showed subtype-, pathway-, and/or genomic aberration-specific responses.
Journal ArticleDOI
Breast cancer genetics: what we know and what we need
TL;DR: High- and low-penetrance breast-cancer-susceptibility alleles are reviewed and ongoing efforts to identify additional susceptibility genes are discussed, which will lead to individualized breast cancer risk assessment and a reduction in breast cancer incidence.